Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

82.64USD
4:00pm EDT
Change (% chg)

$0.35 (+0.43%)
Prev Close
$82.29
Open
$82.30
Day's High
$82.90
Day's Low
$81.84
Volume
1,791,257
Avg. Vol
2,781,245
52-wk High
$86.26
52-wk Low
$63.76

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.16
Market Cap(Mil.): $107,464.70
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Gilead Sciences entered into a $6 bln term loan facility credit agreement - SEC Filing‍​

* Gilead Sciences - On September 8, 2017 co entered into a $6.0 billion term loan facility credit agreement - SEC Filing‍​

Sep 13 2017

BRIEF-Gilead Sciences to present at the Morgan Stanley Global Healthcare conference

* Gilead Sciences to present at the Morgan Stanley global healthcare conference on Monday, September 11 Source text for Eikon: Further company coverage:

Sep 05 2017

BRIEF-Gilead Sciences files for potential mixed shelf size not disclosed

* Gilead Sciences Inc files for potential mixed shelf; size not disclosed - SEC filing‍​ Source text: [http://bit.ly/2etaGsh] Further company coverage:

Aug 31 2017

UPDATE 4-Gilead to buy Kite for promising cancer therapies in $12 bln deal

Aug 28 Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

Aug 28 2017

Gilead to buy Kite for promising cancer therapies in $12 billion deal

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

Aug 28 2017

BRIEF-Gilead says it is not going quiet after Kite deal

* Says it is not going quiet after this deal; will look for more opportunities : conf call

Aug 28 2017

BRIEF-Gilead Sciences to acquire Kite Pharma for $11.9 billion

* Kite Pharma Inc - ‍Gilead will acquire Kite for $180.00 per share in cash​

Aug 28 2017

Gilead to buy Kite Pharma in $11 bln deal - WSJ

Aug 28 Gilead Sciences Inc has agreed to buy Kite Pharma Inc for about $11 billion in an all-cash deal, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Aug 28 2017

BRIEF-Gilead to buy Kite Pharma for roughly $11 billion in cash - WSJ

* Gilead to buy Kite Pharma for roughly $11 billion in cash - WSJ, citing sources Source text - http://on.wsj.com/2giy1NI Further company coverage:

Aug 28 2017

BRIEF-Gilead receives approval in Canada for Vosevi for re-treatment of certain patients with chronic hep c virus infection

* Gilead receives approval in Canada for Vosevi™ (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of certain patients with chronic hepatitis c virus (HCV) infection Source text for Eikon: Further company coverage:

Aug 17 2017

Competitors

Earnings vs. Estimates